Literature DB >> 27121054

Nomogram based on systemic inflammatory response markers predicting the survival of patients with resectable gastric cancer after D2 gastrectomy.

Jianjun Liu1,2, Qirong Geng1,3, Shangxiang Chen1,2, Xuechao Liu1,2, Pengfei Kong1,2, Zhiwei Zhou1,2, Youqing Zhan1,2, Dazhi Xu1,2.   

Abstract

This study aimed to construct a nomogram to predict survival of patients with resectable gastric cancer (RGC) based on both clinicopathology characteristics and systemic inflammatory response markers (SIRMs). Of 3,452 RGC patients after D2 gastrectomy at the Sun Yat-sen University Cancer Center, 1058 patients who met the inclusion criterion were analyzed. The patients operated on from January 1, 2005 to December 31, 2009 were assigned to the training set (817 patients) to establish a nomogram, and the rest (241 patients) were selected as validation set. Based on the training set, seven independent risk factors were selected in the nomogram. The calibration curves for probability of 1-year, 3-year and 5-year overall survival (OS) showed satisfactory accordance between nomogram prediction and actual observation. When the metastatic lymph node stage (mLNS) is replaced by metastasis lymph node ratio (mLNR) in validation set, the C-index in predicting OS rise from 0.77 to 0.79, higher than that of 7th American Joint Committee on Cancer 7th (AJCC) staging system (0.70; p<0.001). In conclusions, the proposed nomogram which including mLNR and routine detected SIRMs resulted in optimal survival prediction for RGC patients after D2 gastrectomy.

Entities:  

Keywords:  nomogram; resectable gastric cancer; survival analysis; systemic inflammatory response

Mesh:

Year:  2016        PMID: 27121054      PMCID: PMC5122331          DOI: 10.18632/oncotarget.8788

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


INTRODUCTION

Gastric cancer is the second leading cause of cancer-related death worldwide, and the 5-year survival is 28% in 2014 [1]. Although the incidence of gastric cancer has declined in the past several years, it remains the most common cancer in many geographic regions, including Eastern Asia, Eastern Europe and Southern/Central American [2]. Currently, the widely used AJCC 7th TNM staging system is the most common tool to predict survival for gastric cancer. It stratifies RGC patients into seven groups [3]. Additionally, our previous study showed the ratio between metastatic and examined lymph nodes (mLNR) based staging system (TRM) is superior to the AJCC 7th system. The new classification can reduce stage migration and provide more reliable prognostic information [4-6]. Recently, nomograms have been established in many types of cancers [7-12]. It is a simple tool to predict individualized survival by incorporating more risk factors such as sex, age and size of the tumor [13]. However, besides tumor-related factors, the survival of cancer patients is also dependent on host's reaction to the tumor. Especially the host inflammatory response markers (SIRMs), a powerful prognostic factors, has not ever been included as a risk group in previous nomograms [14-24]. In this study, we established a nomogram combined clinicopathology characteristics and routine detected SIRMs, to determine whether this model predict a more accurate survival for RGC patients following D2 resection when compared with the currently TNM staging system.

RESULTS

Clinical characteristics of patients

A retrospective study was conducted on a primary cohort, who underwent D2 resection between January 1, 2005 and December 31, 2010 at the Sun Yat-sen University Cancer Center. Of 3,452 RGC patients, 1058 patients met all the inclusion and exclusion criteria. The patients operated between January 1, 2005 and December 31, 2009 were assigned to the training set (817 patients) for the construction of a nomogram, and the rest (241 patients) between January 1, 2010 and December 31, 2010 were selected as validation set. The characteristics of those patients are listed in Table 1. The median follow-up is 39.4 months in training set and 28.6 months in validation set.
Table 1

Characteristic of training set and validation set

Training set(n=817)Validation set(n=241)p
NO. of patients%NO. of patients%
Age (years)0.450
  Median57.7±11.958.7±11.4
  Range19 to 8921 to 81
Sex0.295
  Male54767.017070.5
  Female27033.07129.5
Tumor size (cm)0.170
  Mean±SD4.6±2.74.3±2.4
  Range0.2 to 21.00.8 to 14.0
Tumor location0.555
  Upper34241.99338.6
  Middle16019.64619.1
  Lower31538.610242.3
Pathology type0.008
  Differentiated28935.410844.8
  Undifferentiated52864.613355.2
Depth of invasion0.001
  Mucosa or submucosa10713.13514.5
  Proper muscle8210.03213.3
  Subserosa16320.010443.2
  Serosa36344.46024.9
  Adjacent invasion10212.5104.1
Positive LN (Mean±SD)6.2±8.55.7±7.70.380
Total LN (Mean±SD)25.0±11.724.6±11.10.692
mLNR (Mean±SD)0.2±0.30.2±0.30.138
AJCC 7th Stage0.002
  IA8310.22912.0
  IB617.5229.1
  IIA577.03213.3
  IIB13416.43614.9
  IIIA8810.83414.1
  IIIB16720.44819.9
  IIIC22727.84016.6
CEA (ug/ml)11.3±52.412.5±57.60.676
Total Protein (g/l)67.2±6.768.9±6.20.155
Albumin (g/l)41.2±4.341.5±3.90.226
Globin (g/l)26.0±4.427.3±4.20.448
C-reactive protein (mg/l)8.2±19.99.3±31.00.337
CAR(mg/g)0.245
  ≤0.0541851.212451.5
  0.05-0.1821225.97531.1
  ≥0.1818722.94217.4
WBC (×109/l)6.6±1.86.5±1.60.066
Hemoglobin (g/l)123.0±24.4129.1±24.30.105
Neutrophil (×109/l)4.0±1.54.1±1.40.083
Lymphocyte (×109/l)1.9±0.61.8±0.60.063
Palate (×109/l)252.9±97.2244.1±79.50.074
NLR0.936
  ≤1.3013616.6197.9
  1.30-3.7158972.119078.8
  ≥3.719211.33213.3

Abbreviation: LN, lymph node; mLNR, metastatic lymph node ratio; AJCC, American joint Committee on Cancer; GB, globin; CAR, C-reactive protein to albumin ratio; NLR, neutrophil to lymphocyte ratio.

Abbreviation: LN, lymph node; mLNR, metastatic lymph node ratio; AJCC, American joint Committee on Cancer; GB, globin; CAR, C-reactive protein to albumin ratio; NLR, neutrophil to lymphocyte ratio.

Independent risk factors in the training set

In the current study, the best cutoff points for C-reactive protein to albumin ratio (CAR) were 0.05 and 0.18 (Supplementary Figure S1). And the best cutoff points for Neutrophil to lymphocyte ratio (NLR) were 1.30 and 3.71 (Supplementary Figure S2). Univariate analysis showed that the age at diagnosis, location, pathological type, depth of invasion, mLNS, mLNR, AJCC 7th stage, NLR, ALB, CRP, CEA and CAR were associated with OS. Multivariate analysis with Cox PH regression showed that age at diagnosis, location, pathological type, depth of invasion, mLNS/mLNR, NLR and CAR were independent risks for overall survival (Table 2). Based on the multivariate analysis, six models were constructed: AJCC staging system; Nomogram A based on AJCC staging system and SIRMs; Nomogram B based on mLNS; Nomogram C based on mLNR; Nomogram D based on mLNS and SIRMs; Nomogram E based on mLNR and SIRMs.
Table 2

Multivariate Analysis of the training set

Hazard ratio95% CIp
Age1.021.01 to 1.03<0.001
Location<0.001
  Lowerref
  Middle1.621.17 to 2.24
  Upper1.811.38 to 2.36
Pathological type0.640.50 to 0.81<0.001
Depth of invasion<0.001
  Mucosa or submucosaref
  Proper muscle2.140.88 to 5.23
  Subserosa2.881.28 to 6.42
  Serosa3.971.83 to 8.64
  Adjacent invasion5.112.28 to 11.45
mLNR7.995.47 to 11.67<0.001
CAR<0.001
  ≤0.05ref
  0.05-0.181.321.00 to 1.75
  ≥0.182.271.73 to 2.97
NLR0.019
  ≤1.30ref
  1.30-3.711.410.96 to 2.06
  ≥3.711.911.21 to 3.03

Abbreviation: mLNR, metastatic lymph node ratio; NLR, neutrophil to lymphocyte ratio; CAR, C-reactive protein to albumin ratio.

Abbreviation: mLNR, metastatic lymph node ratio; NLR, neutrophil to lymphocyte ratio; CAR, C-reactive protein to albumin ratio.

Development and validated the nomogram for gastric cancer

The risk factors which were statistically significant in multivariate analysis were incorporated intothe prognostic nomogram (Figure 1). When the nomogram including depth of invasion, mLNS, age, location, pathological type and SIRMs, the C-index for predicting OS was 0.77, which were significantly lower than that of the nomogram including depth of invasion, mLNR, age, location, pathological type and SIRMs (0.80; p =0.005). It suggests that the discrimination power of mLNR is better than mLNS in this nomogram. Additionally, according to the total score identified on the points scale, the current nomogram clearly assigned the probability of 1-year, 3-year and 5-year OS.
Figure 1

Nomogram predicting 1-year, 3-year and 5-year OS for RGC patients after D2 resection

The nomogram is used by adding up the points identified on the points scale for each variable. According to the sum of these points projected on the bottom scales, the nomogram can provide the likehood of 1-year, 3-year and 5-year OS for an individual patient. Abbreviation: mLNR, metastatic lymph node ratio; NLR, neutrophil to lymphocyte ratio; CAR, C-reactive protein to Albumin ratio; OS, overall survival; RGC, resectable gastric cancer.

Nomogram predicting 1-year, 3-year and 5-year OS for RGC patients after D2 resection

The nomogram is used by adding up the points identified on the points scale for each variable. According to the sum of these points projected on the bottom scales, the nomogram can provide the likehood of 1-year, 3-year and 5-year OS for an individual patient. Abbreviation: mLNR, metastatic lymph node ratio; NLR, neutrophil to lymphocyte ratio; CAR, C-reactive protein to Albumin ratio; OS, overall survival; RGC, resectable gastric cancer.

Validation of predictive accuracy for OS of the nomogram

In the validation set, the C-index of the nomogram included mLNR for predicting OS was 0.79 (95% CIs 0.74-0.84; p<0.001), higher than that of AJCC 7th staging system(C-index=0.70; 95% CIs 0.64-0.76; p<0.001). Furthermore, as shown in Figure 2, the probability of 1-year, 3-year and 5-year survival in this nomogram corresponded closely between prediction and observation. In addition, Figure 3A shows the Kaplan-Meier survival curve of the primary cohort categorized by the AJCC 7th staging system, with no good discrimination between stage I and stage II patients. However, by the proposed nomogram, a wider range of predicted survival than AJCC-TNM staging system could be clearly identified within each TNM categories (Figure 3B).
Figure 2

The calibration curve for predicting patients overall survival at 1-year

A. 3-year B. and 5-year C. in the training set and predicting overall survival at 1-year D. and 3-year E. in the validation set, 5-year F. in the primary cohort. The X-axis represents the nomogram-predicted survival, and the actual survival is plotted on the Y-axis. The dotted line represents the ideal correlationship between predicted and actual survival.

Figure 3

A. Overall survival by AJCC 7th staging system in primary cohort; B. Distribution of nomogram-predicted 5-year overall survival within each AJCC 7th stage grouping.

The calibration curve for predicting patients overall survival at 1-year

A. 3-year B. and 5-year C. in the training set and predicting overall survival at 1-year D. and 3-year E. in the validation set, 5-year F. in the primary cohort. The X-axis represents the nomogram-predicted survival, and the actual survival is plotted on the Y-axis. The dotted line represents the ideal correlationship between predicted and actual survival. A. Overall survival by AJCC 7th staging system in primary cohort; B. Distribution of nomogram-predicted 5-year overall survival within each AJCC 7th stage grouping.

Comparison of predictive accuracy for OS in different nomogram models

As shown in Figure 4, our nomogram displayed optimal outcome-predicting accuracy in the validation set. The C-index of the proposed Nomogram was 0.79, which was higher than the AJCC 7th staging system (0.70), the potential Nomogram A (0.76, P<0.001), the potential Nomogram B (0.73, P<0.001), the potential Nomogram C (0.75, P<0.001) and the potential Nomogram D (0.77, P=0.005). These results indicated that the proposed nomogram was a useful predictor in predicting both short- and long-term survival of patients with RGC after D2 resection.
Figure 4

The C-index for OS in different nomogram models

Nomogram A including depth of invasion, mLNS, age, location and pathological type; Nomogram B including depth of invasion, mLNR, age, location and pathological type; Nomogram C including depth of invasion, mLNS, age, location, pathological type and SIRMs. Nomogram (proposed) including depth of invasion, mLNR, age, location, pathological type and SIRMs. Abbreviation: mLNS, metastatic lymph node stage; mLNR, metastatic lymph node ratio.

The C-index for OS in different nomogram models

Nomogram A including depth of invasion, mLNS, age, location and pathological type; Nomogram B including depth of invasion, mLNR, age, location and pathological type; Nomogram C including depth of invasion, mLNS, age, location, pathological type and SIRMs. Nomogram (proposed) including depth of invasion, mLNR, age, location, pathological type and SIRMs. Abbreviation: mLNS, metastatic lymph node stage; mLNR, metastatic lymph node ratio.

DISCUSSION

In the present study, we established a nomogram based on all the selected independent risk factors for RGC patients after D2 gastrectomy. Especially, inflammatory response markers were included in nomogram for the first time and showed a much more precise prediction for the prognosis of RGC. When we constructed a nomogram that only included age at diagnosis, location, depth of invasion, mLNS, and pathological type, the C-index for OS prediction was 0.73, higher than that of the AJCC 7th staging system (0.73 vs 0.70, respectively). The result is consistent with the previous studies. For example, Han et al developed a nomogram to predict the probability of 2-year and 5-year survival in 2012 [25]. Hirabayashi et al also constructed and validated a nomogram for overall survival in serosa-negative, locally advanced gastric cancer [26]. Both of the nomograms show more accurate prognosis prediction than the TNM staging system. Recently, mLNR has been proved to be superior to the number of positive lymph node in the accuracy of prognosis prediction [4, 6, 27, 28]. In this study, mLNR was also testified as an independent risk factor for gastric cancer. Interestingly, when mLNS was replaced by mLNR in training set, the C-index raised from 0.73 to 0.75, which was consistent with previous study [29]. Furthermore, when we added routine detected SIRMs into the nomogram, C-index of our nomogram raised to 0.79. Therefore, the proposed nomogram based on mLNR and other clinical pathology characteristics and SIRMs could make a much more precise prediction than other models for survival of RGC patients after D2 gastrectomy. Indeed, the pathogenesis of tumor is closely linked to inflammatory. By promoting cell proliferation and angiogenesis, the inflammatory response can stimulate carcinogenesis [30]. Currently, we collect white blood cell count, neutrophil count, lymphocyte count, platelet count, total protein, albumin (ALB), globulin and C-reactive protein (CRP) in the training set. In contrast to other inflammation-related cytokines, the included SIRMs in this study is readily available and relatively cheap. All of them are evaluated in daily clinical routine worldwide [19]. During the past years, many studies have demonstrated the prognostic value of these routine detected SIRMs in gastric cancer patients. For example, Nozoe et al investigated 232 cases and pointed that Glasgow prognostic score (GPS), an inflammation-based prognostic score that combines CRP and ALB, can predict the prognosis of patients with operable gastric cancer. [20] Jung et al detected the significance of the NLR in late stage gastric cancer following resection. They suggested that the elevated preoperative NLR could predict the survival of patients and be utilized as a reliable prognostic indicator for risk stratification [21]. Some possible mechanisms could explain the relationship between the SIRMs and prognosis in RGC patients. First, these SIRMs like the high CRP level, could reflect progressive nutritional and functional decline of gastric cancer patients [31]. Second, these indexes are associated with the inherent immune system, such as macrophage function [32]. In addition, inflammatory response can directly promote angiogenesis and tumor metastasis [14]. There are several potential limitations in our study. Firstly, because of the insufficient of samples and observations, several known variables may not be included in the nomogram models. Secondly, the current nomogram was developed based on data obtained from China. Different from the Japan and Korea, most gastric cancer patients in China are often treated at advanced stage. Whether this nomogram is applicable to other regions is still uncertain. To the best of our knowledge, this study is the first attempt to develop a prognostic nomogram which combines clinicopathology characteristics and routine detected SIRMs. Compared with previous prognostic models and the AJCC 7th staging system, the current nomogram represents the optimum prognostic discrimination and a better predictive accuracy for survival. It can be used to calculate individualized survival prediction and provide better treatment allocation after D2 gastrectomy. However, further validation whether this nomogram is applicable to all the RGC patients is required.

MATERIALS AND METHODS

Patients

From January 1, 2005 to December 31, 2010, among gastric cancer patients after D2 gastrectomy at the Department of Gastric and Pancreatic Surgery at the Sun Yat-sen University Cancer Center, we collected the data of RGC patients who met the following inclusion criteria: no history of receiving anti-cancer therapy before surgery; no history of chronic infectious diseases (e.g. hepatitis, tuberculosis) or inflammatory diseases; no history of liver and kidney dysfunctions; no history of other malignancies; complete resection of cancer with D2 lymphadenectomy. Ethical approval was obtained before surgery. The data of patients' clinicpathological characteristics (location, size, histology, depth of invasion, mLNS, mLNR) and the routine pretreatment blood SIRMs (white blood cell count, neutrophil count, lymphocyte count, platelet count, total protein, ALB, globulin, CRP were collected. The tumor location was categorized as upper, middle and lower by the center of the lesion. Histology was categorized by differentiated type (papillary adenocarcinoma, well-differentiated tubular adenocarcinoma, and moderately differentiated tubular adenocarcinoma) and undifferentiated type (poorly differentiated tubular adenocarcinoma, signet ring cell carcinoma, and mucinous adenocarcinoma) [25]. The depth of invasion was categorized by mucosa or submucosa, proper muscle, subs-serosa, serosa and adjacent invasion. The pathological tumor stage (IA, IB, IIA, IIB, IIIA, IIIB or IIIC) and mLNS (0, 1~2, 3~6, 7~15 or >16) were categorized according to the AJCC 7th TNM staging system. [3] The mLNR was calculated as the number of positive lymph nodes divided by the number of examined lymph nodes. NLR was defined as neutrophil count divided by lymphocyte count. The CAR was defined as CRP divided by ALB. Follow-up duration was measured as the time from the date of surgery to the last follow-up. OS was defined as the time form surgery to death due to any cause or the last follow-up. The survival status was recorded according to the latest follow-up.

Follow up

Postoperative follow-up included clinical and laboratory examinations every 3 months for the first 2 years, every 6 months from the 3rd to 5th year, annually after the gastrectomy or until the patient died.

Statistics analysis

Based on clinical findings, categorical variables were grouped before modeling. The best cutoff points for continuous variables were performed by X-tile (http://www.tissuearray.org/rimmlab/). The continuous variables were divided into three groups. Associations between each group can be calculated by various standard statistical tests, including the log-rank test for survival and means tests for associations between other marker data. The X-tile can provide the optimal division of the data by P values obtained from a lookup table [33]. Independent risk factors were identified by the forward method. OS estimation and survival curves were performed by the Kaplan-Meier method and valided by the log-rank test. Nomogram was established based on the training set data, and Cox PH regression was used for screening independent risk factors. On the basis of all the independent prognostic factors, a nomogram was constructed by using the package of rms in R software version 3.1.3 (http://www.r-project.org/) for predicting 1-year, 3-year, 5-year overall survival. We used the method of bootstraps with 1000 resample for these activities. Harrell's C-index was used in the nomogram for evaluating the discrimination [34]. It can estimate the probability of concordance between the observed and predicted OS. The higher the C-index, the more precise was the survival prediction. The validation was carried out by using the validation set. Discrimination between the proposed nomogram and AJCC 7th staging system was performed with the roccp.cens package in R soft. According to the nomogram-predicted probabilities, calibration were carried out by grouping all the training set patients, validation set and primary cohort, then the mean of the groups were compared with observed Kaplan-Meier OS estimation. P value <0.05 was considered to be statistically significant. All analyses were performed by the software statistical package for social sciences version 19.0 (SPSS, Chicago, IL) and the R software version 3.13 (http://www.r-project.org/).
  33 in total

1.  Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer.

Authors:  Mi Ran Jung; Young Kyu Park; Oh Jeong; Jang Won Seon; Seong Yeob Ryu; Dong Yi Kim; Young Jin Kim
Journal:  J Surg Oncol       Date:  2011-05-25       Impact factor: 3.454

2.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

Authors:  M W Kattan; J A Eastham; A M Stapleton; T M Wheeler; P T Scardino
Journal:  J Natl Cancer Inst       Date:  1998-05-20       Impact factor: 13.506

3.  Evaluating the yield of medical tests.

Authors:  F E Harrell; R M Califf; D B Pryor; K L Lee; R A Rosati
Journal:  JAMA       Date:  1982-05-14       Impact factor: 56.272

4.  Tumor-ratio-metastasis staging system as an alternative to the 7th edition UICC TNM system in gastric cancer after D2 resection--results of a single-institution study of 1343 Chinese patients.

Authors:  W Wang; D Z Xu; Y F Li; Y X Guan; X W Sun; Y B Chen; R Kesari; C Y Huang; W Li; Y Q Zhan; Z W Zhou
Journal:  Ann Oncol       Date:  2011-02-10       Impact factor: 32.976

5.  X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.

Authors:  Robert L Camp; Marisa Dolled-Filhart; David L Rimm
Journal:  Clin Cancer Res       Date:  2004-11-01       Impact factor: 12.531

6.  Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer.

Authors:  Markus Riester; Jennifer M Taylor; Andrew Feifer; Theresa Koppie; Jonathan E Rosenberg; Robert J Downey; Bernard H Bochner; Franziska Michor
Journal:  Clin Cancer Res       Date:  2012-01-06       Impact factor: 12.531

7.  High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.

Authors:  Steven C H Kao; Nick Pavlakis; Rozelle Harvie; Janette L Vardy; Michael J Boyer; Nico van Zandwijk; Stephen J Clarke
Journal:  Clin Cancer Res       Date:  2010-10-18       Impact factor: 12.531

8.  Development and external validation of a nomogram for overall survival after curative resection in serosa-negative, locally advanced gastric cancer.

Authors:  S Hirabayashi; S Kosugi; Y Isobe; A Nashimoto; I Oda; K Hayashi; I Miyashiro; S Tsujitani; Y Kodera; Y Seto; H Furukawa; H Ono; S Tanabe; M Kaminishi; S Nunobe; T Fukagawa; R Matsuo; T Nagai; H Katai; T Wakai; K Akazawa
Journal:  Ann Oncol       Date:  2014-03-24       Impact factor: 32.976

9.  Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer.

Authors:  X Jiang; N Hiki; S Nunobe; K Kumagai; T Kubota; S Aikou; T Sano; T Yamaguchi
Journal:  Br J Cancer       Date:  2012-06-19       Impact factor: 7.640

10.  Prognostic score models for survival of nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy and chemotherapy.

Authors:  Lei Zeng; Pi Guo; Jin-Gao Li; Fei Han; Qiang Li; Yong Lu; Xiao-Wu Deng; Qing-Ying Zhang; Tai-Xiang Lu
Journal:  Oncotarget       Date:  2015-11-17
View more
  13 in total

1.  Validation of the Memorial Sloan Kettering Gastric Cancer Post-Resection Survival Nomogram: Does It Stand the Test of Time?

Authors:  Masaya Nakauchi; Colin M Court; Laura H Tang; Mithat Gönen; Yelena Y Janjigian; Steven B Maron; Daniela Molena; Daniel G Coit; Murray F Brennan; Vivian E Strong
Journal:  J Am Coll Surg       Date:  2022-04-28       Impact factor: 6.532

2.  Nomogram predicts survival benefit from preoperative radiotherapy for non-metastatic breast cancer: A SEER-based study.

Authors:  Jianjun Liu; Mingxue Su; Shikai Hong; Hong Gao; Xucai Zheng; Shengying Wang
Journal:  Oncotarget       Date:  2017-07-25

3.  Preoperative lymphocyte-to-monocyte ratio represents a superior predictor compared with neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios for colorectal liver-only metastases survival.

Authors:  Jianhong Peng; Hui Li; Qingjian Ou; Junzhong Lin; Xiaojun Wu; Zhenhai Lu; Yunfei Yuan; Desen Wan; Yujing Fang; Zhizhong Pan
Journal:  Onco Targets Ther       Date:  2017-07-27       Impact factor: 4.147

Review 4.  Prognostic role of platelet to lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Yongzhao Zhao; Guangyan Si; Fengshang Zhu; Jialiang Hui; Shangli Cai; Chenshen Huang; Sijin Cheng; Abdel Hamid Fathy; Yi Xiang; Jing Li
Journal:  Oncotarget       Date:  2017-04-04

5.  Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor.

Authors:  Minyong Kang; Chang Wook Jeong; Cheol Kwak; Hyeon Hoe Kim; Ja Hyeon Ku
Journal:  Oncotarget       Date:  2017-02-21

6.  Use of the combination of the preoperative platelet-to-lymphocyte ratio and tumor characteristics to predict peritoneal metastasis in patients with gastric cancer.

Authors:  Xiao-Dong Chen; Chen-Chen Mao; Rui-Sen Wu; Wei-Teng Zhang; Ji Lin; Xiang-Wei Sun; Chu-Huai Chi; Neng Lou; Peng-Fei Wang; Xian Shen; Guan-Bao Zhu; Shu-Rong Shen
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

Review 7.  Prediction models for patients with esophageal or gastric cancer: A systematic review and meta-analysis.

Authors:  H G van den Boorn; E G Engelhardt; J van Kleef; M A G Sprangers; M G H van Oijen; A Abu-Hanna; A H Zwinderman; V M H Coupé; H W M van Laarhoven
Journal:  PLoS One       Date:  2018-02-08       Impact factor: 3.240

8.  Evolving role of FDG-PET/CT in prognostic evaluation of resectable gastric cancer.

Authors:  Emilio De Raffele; Mariateresa Mirarchi; Dajana Cuicchi; Ferdinando Lecce; Bruno Cola
Journal:  World J Gastroenterol       Date:  2017-10-14       Impact factor: 5.742

9.  Inflammatory markers for predicting overall survival in gastric cancer patients: A systematic review and meta-analysis.

Authors:  Mi-Rae Kim; A-Sol Kim; Hye-In Choi; Jae-Hun Jung; Ji Yeon Park; Hae-Jin Ko
Journal:  PLoS One       Date:  2020-07-27       Impact factor: 3.240

10.  Development and Validation of a Nomogram to Predict the Benefit of Adjuvant Radiotherapy for Patients with Resected Gastric Cancer.

Authors:  Shu-Qiang Yuan; Wen-Jing Wu; Miao-Zhen Qiu; Zi-Xian Wang; Lu-Ping Yang; Ying Jin; Jing-Ping Yun; Yuan-Hong Gao; Yu-Hong Li; Zhi-Wei Zhou; Feng Wang; Rui-Hua Xu
Journal:  J Cancer       Date:  2017-09-29       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.